Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022)